Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genmab Geared Up To Launch Epkinly With AbbVie

As FDA Approves CD20xCD3 Bispecific For Lymphoma

Executive Summary

The Danish group, along with partner AbbVie, is all set for a commercial battle with Roche as Epkinly hits the US market for refractory diffuse large B-cell lymphoma a few weeks ahead of expected approval for the Swiss major’s same-in-class rival glofitamab.

You may also be interested in...



EMA OKs Seven New Drugs Including First RSV Vaccine For Older Adults

GSK’s Arexvy vaccine for preventing lower respiratory tract disease caused by respiratory syncytial virus in adults aged 60 years and older is among the latest products that the European Medicines Agency said should be approved for use in the EU.

Physicians Ponder CD20 Bispecifics’ Transition To Community As Lunsumio US Debut Approaches

Management of CRS will take getting used to, while B-cell aplasia takes on a new importance in the pandemic era, according to presentations at ASH.

Roche Notches Up First Approval For CD20xCD3 Bispecific Lunsumio

Roche has gained approval for the first of its two bispecific therapies for lymphoma, but will face stiff competition from Genmab and AbbVie’s late-stage rival.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel